Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer

Author:

Jiang Yuyan1,Jin Jiahui2,Fan Jingzheng3,Huang Chao4,Jia Qiang1,Tan Jian1,He Xianghui5,Zheng Xiangqian6,Zhao Yue7,Zhang Qing7,Meng Zhaowei1ORCID,Wang Yan2

Affiliation:

1. Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, PR China

2. Tianjin University of Traditional Chinese Medicine, Jian Kang Chan Ye Yuan, Tianjin, PR China

3. Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin, PR China

4. Hull York Medical School, University of Hull, Hull, UK

5. Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, PR China

6. Department of Thyroid & Neck Tumor, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention & Therapy of Tianjin City, Tianjin, PR China

7. Department of Health Management, Tianjin Medical University General Hospital, Tianjin, PR China

Abstract

Aim: Urinary iodine concentration (UIC) may assess radioactive iodine ablation. Materials & methods: According the 2015 American Thyroid Association guidelines, patients were categorized into low- to intermediate-risk or high-risk groups. The iodine concentration in the morning urine specimens was measured by the ceric ion-arsenious acid method. Results: In the low- to intermediate-risk group (113 cases), nonexcellent response (non-ER) was associated with higher UIC, higher UIC subgroups (p < 0.05), higher pre-ablative stimulated thyroglobulin levels (p < 0.01). In the high-risk group (68 cases), the non-ER rate was higher in the higher pre-ablative stimulated thyroglobulin group (p < 0.01), but not significantly different between the UIC and UIC subgroups (p > 0.05). Conclusion: The non-ER rate was related to UIC in the low- to intermediate-risk group; however, UIC did not affect the non-ER rate in the high-risk group.

Funder

National Natural Science Foundation of China

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3